Release Date: June 5, 2024
Expiration Date: June 5, 2027
This recorded webinar provides an introduction to restorative stimulation and explores the role of muscle function and motor control in chronic low back pain (CLBP). Faculty experts discuss best practices for identifying appropriate patients for restorative stimulation therapy, including clinical indicators, physical examination techniques, and key imaging findings associated with multifidus dysfunction. The activity also reviews the clinical evidence supporting restorative stimulation, including long-term 5-year outcomes data.
Through this on-demand activity, learners will gain practical insight into recognizing patients with multifidus dysfunction, understanding the relationship between dysfunction and restoration, and evaluating the clinical data supporting restorative stimulation therapy.Please note: this webinar is available for educational purposes only and has not been accredited for CME credit.
To access the NANS eLearning Center and register for this content, log in using your NANS account username and password.
Following participation in this activity, learners will be able to:
Welcome & IntroductionCasey Grillo, NP & Nicole Busch, NPIdentifying Patients for Restorative StimulationChris Gilligan MDMike Fennick, DNP, RN, AGPCNP-BCKristen Klein, NP
None of the planners, staff, reviewers or faculty have any relevant financial relationships to disclose with ACCME ineligible companies except those listed below. All relevant relationships have been mitigated. Disclosures
Casey Grillo
Planner
Abbott/St. Jude Medical; Nalu
Consulting Fee
Nicole Busch
CornerLoc/TransLoc
Kristen Klein
Faculty
Mainstay Medical; Boston Scientific, Nevro, Vertos
Chris Gilligan
Mainstay Medical
Stock Options
Saluda Medical; Mainstay Medical; Persica, and Iliad Lifesciences
Mark N. Malinowski
Webinar Subcommittee Chair, Reviewer
Abbott/ St. Jude Medical; Biotronik
Nalu Medical; SI Bone, Inc. (relationships ended)
Jeffrey Raskin
Webinar Subcommittee Reviewer
Synergia; Medtronic; Iota; BlackRock Neurotech